Mr. Stephen Van Deventer reports

PREVECEUTICAL PROVIDES UPDATE ON PLAN OF ARRANGEMENT WITH BIOGENE THERAPEUTICS INC.

Further to Preveceutical Medical Inc.'s news releases of Sept. 4, 2025, Sept. 19, 2025, Oct. 10, 2025, and Oct. 20, 2025, the company will be completing its previously announced plan of arrangement to be effected under Part 9, Division 5, of the Business Corporations Act (British Columbia) with BioGene Therapeutics Inc. effective Monday, Nov. 24, 2025. Shareholders of record on Nov. 24, 2025, will be issued new common shares of Preveceutical and 0.2 of one share of BioGene Therapeutics. The news release of Oct. 20, 2025, incorrectly stated that the record date was Oct. 31, 2025.

About Preveceutical Medical Inc.

Preveceutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products. Preveceutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual-gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel program; nature-identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

We seek Safe Harbor.